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VOLUME 49 | NUMBER 12 | DECEMBER 2017 Nature GeNetics A r t i c l e s measures single-nucleotide variants, small insertions/deletions (indels), gene rearrangements/fusions, and copy number gain (CNG) across 68 clinically relevant cancer genes 9, 10 (Supplementary Table 2 and Online Methods). We defined the landscape of somatic genetic alterations present in 1,122 EGFR-mutation-positive and 1,008 EGFRmutation-negative patients with advanced-stage (stage III or IV) NSCLC (Supplementary Tables 3 and 4 and Supplementary Data Sets 1 and 2).
We filtered for mutations that were nonsynonymous and were validated or predicted to affect gene function (Online Methods), a process yielding 1,122 EGFR-mutation-positive and 944 EGFR-mutation-negative cases. This data set of advanced-stage EGFR-mutant samples differs from The Cancer Genome Atlas (TCGA) and other genomic compendia of lung cancer that largely contain early-stage tumors.
Analysis of the 1,122 EGFR-mutant patient cohort showed the widespread presence of co-occurring genetic alterations, in addition to the EGFR driver mutation (Fig. 1a) . The EGFR-mutant cases contained 2.58 ± 1.7 (mean ± s.e.m) genetic alterations beyond EGFR (out of the 68 genes profiled). When the EGFR mutation was included, the range of detectable alterations was 1-13. Most patients (92.9%; 1,043/1,122) had at least one additional variant of known or likely functional importance beyond the EGFR driver mutation (Supplementary Data Set 1). Most (89.8%; 3,033/3,375) of the genetic comutations present in the EGFR-mutation-positive cohort had verified or likely functional effects (on the basis of in silico modeling; Online Methods and Supplementary Data Set 1), and only 10.2% (345/3,375) of these comutations were classified as likely passenger events (with neutral or unknown functional effects). Of the mutations present in the EGFR-mutation-negative cohort, 16 .1% (415/2,578) were classified as passenger events (P = 1.3 × 10 −11 , two-tailed Fisher's exact test, odds ratio (OR) = 0.64, proportions test, Supplementary Data Set 2; comparison of the prevalence of mutations classified as passenger events in the EGFRmutation-positive cohort versus the EGFR-mutation-negative cohort) (Fig. 1a,b and Supplementary Table 3 ). The data showed that canonical EGFR driver mutations co-occurred with oncogenic driver alterations in several other genes, including PIK3CA, BRAF, MET, MYC, CDK6, and CTNNB1. Comparison of the frequency of genetic co-alterations present in the EGFR-mutation-positive samples (n = 1,122) with those present in the stage-matched EGFR-mutation-negative samples (n = 944) showed significant enrichment for certain genetic events (q values determined by two-tailed Fisher's exact test with BenjaminiHochberg correction for multiple hypotheses) within the EGFR-mutant cancers (Supplementary Table 3 ). There was enrichment for co-alterations in CTNNB1 (frequency of alteration in EGFR-mutation-positive cases, 5.3% (60/1,122) versus EGFR-mutation-negative cases, 1.8% (17/944), q = 2.0 × 10 −4 ), CDK6 (frequency of alteration in EGFR-mutation-positive cases 7.0% (79/1,122) versus EGFR-mutation-negative cases 3.1% (30/944), q = 8.0 × 10 −4 ), and AR (frequency of alteration in EGFR-mutation-positive cases, 5.1% (57/1,122) versus EGFR-mutationnegative cases, 2.6% (25/944), q = 0.02), and a modest difference in TP53 (frequency of alteration in EGFR-mutation-positive cases, 54.6% (613/1,122) versus EGFR-mutation-negative cases, 50.3% (475/944), q = 0.14) in the EGFR-mutant cohort (n = 1,122) compared with the stage-matched EGFR-mutation-negative samples (n = 944) ( Fig. 1a- 
d, Supplementary Table 3 and Supplementary Data Sets 1 and 2).
Pathway-level analysis showed selection for co-alterations in multiple WNT/CTNNB1-pathway genes (144/1,122 versus 92/944, q = 0.06) and genes encoding hormone signaling proteins (59/1,122 versus 29/944, q = 0.04) in the EGFR-mutant cohort, whereas alterations in receptor-tyrosine-kinase genes (310/1,122 versus 361/944, q = 2.0 × 10 −06 ) and MAPK-pathway genes (e.g., KRAS, with 291/1,122 versus 453/944, q = 2.8 × 10 −24 , and gene fusions, e.g., ALK, with 48/1,122 versus 67/944, q = 0.02) were enriched in the EGFR-mutation-negative cohort ( Fig. 1e and Supplementary Table 2) . This large-scale data set uncovered a potential role for WNT/CTNNB1 and cell-cycle-gene aberrations in the pathogenesis of advanced-stage EGFR-mutant NSCLC.
The EGFR p.Thr790Met mutation arises in over 50% of cases of acquired resistance to first-generation EGFR tyrosine kinase inhibitors (TKIs; erlotinib, gefitinib) 11 but is rarely detected (~0.5%) before EGFR TKI treatment 12 . In the cohort of 1,122 EGFR-mutant NSCLC samples, 440 had a detectable alteration in EGFR encoding the p.Thr790Met mutation. On the basis of the rare detection of EGFR p.Thr790Met in EGFR TKI-naive patients (0.5%) 12 , it is likely that most of these EGFR p.Thr790Met-positive patients were treated previously with a first-generation (or second-generation) EGFR TKI. Similarly to the presumed mutual exclusivity of oncogenic driver mutations in treatment-naive NSCLC, EGFR TKI treatment resistance is considered to be largely a consequence of a single gene alteration, such as that encoding the EGFR p.Thr790Met mutation, which is thought to be sufficient to drive acquired resistance to firstgeneration EGFR TKIs in an individual patient 11 . Using our large clinical cohort (n = 440 EGFR p.Thr790Met-positive cases), we tested whether specific genetic co-alterations tended to co-occur with EGFR p.Thr790Met; the co-occurrence would suggest a functional role for such co-altered genes in driving EGFR TKI resistance in cooperation with EGFR p.Thr790Met. We found an increase in the mean number of detectable genetic alterations in EGFR p.Thr790Met-positive (2.41 ± 1.89) compared with EGFR p.Thr790Met-negative (2.01 ± 1.77) patients (P = 4.5 × 10 −04 , two-tailed Fisher's exact test; Supplementary Table 4 ). In the EGFR p.Thr790Met-positive cases (n = 440) compared with the EGFR p.Thr790Met-negative cases (n = 682) (q values determined by two-tailed Fisher's exact test with BenjaminiHochberg correction for multiple hypotheses), we observed more frequent alterations in cell-cycle genes (CDK6 CNG, 43/440 versus 36/682, q = 0.08; CCNE1 CNG, 39/440 versus 39/682, q = 0.28), WNTpathway genes (CTNNB1 oncogenic mutations, 33/440 versus 27/682, q = 0.12), genes encoding hormone-signaling proteins (AR somatic mutations, 30/440 versus 27/682, q = 0.22), epigenetic-pathway genes (MYC CNG, 47/440 versus 41/682, q = 0.08), and KRAS (CNG and oncogenic mutations, 21/440 versus 17/682, q = 0.24), PDGFRA (CNG and oncogenic mutations, 21/440 versus 11/682, q = 0.06), and BRCA1 (31/440 versus 24/682, q = 0.10) (Fig. 2a-e, Supplementary Fig. 1a- Fig. 2f ). The finding of co-occurring oncogenic mutations in KRAS and EGFR was consistent with preclinical data 13, 14 . In a subgroup analysis of cases positive for the EGFR p.Cys797Ser mutation (n = 15), which can arise upon acquired resistance to osimertinib (the approved thirdgeneration EGFR TKI with activity against EGFR p.Thr790Met 15 ), there were recurrent activating alterations in MAPK-pathway genes (including KRAS CNG and oncogenic mutations), cell-cycle genes (CDK4 and CDK6), and AR CNGs (Supplementary Fig. 1c ). These data identified extensive co-occurring alterations in advanced-stage EGFR-mutant NSCLCs, even those with EGFR TKI-resistant forms of mutant EGFR (p.Thr790Met and p.Cys797Ser).
A r t i c l e s cfDNA and clinical outcomes in EGFR-mutant lung cancers
We next examined the landscape of somatic genetic alterations present in a cohort of patients with advanced-stage EGFR-mutant NSCLC for whom longitudinal cfDNA analysis and clinical context and treatment response data were available (n = 137 samples from 97 patients; Fig. 3a and Supplementary A r t i c l e s who were TKI naive (n = 21), who showed disease progression on first-line TKI treatment (n = 53), and who showed disease progression on second-line therapy (n = 26). Fig. 3b and Supplementary Fig. 2a-c) . Enrichment for the EGFR p.Thr790Met alteration occurred in samples with progression on firstline EGFR TKI (31/53 versus 0/21, q = 3.6 × 10 −5 ), as expected on the basis of the rare detection (~0.5%) of the p.Thr790Met alteration before first-generation EGFR TKI treatment 12 and established the incidence of this alteration (55-65%) at acquired resistance to A r t i c l e s Osimertinib nonresponders (n = 21)
Osimertinib responder (n = 20) Figure 5 Longitudinal genomic analysis of tumor and cfDNA in a patient with EGFR-mutant lung cancer from diagnosis to death. (a) Heat map depicting the clonal status of nonsynonymous somatic mutations including SNVs, dinucleotides, and indels from each sequenced region of the patient's disease, as determined by the subclonal copy number-corrected cancer cell fraction and PyClone cross-sample clustering. Somatic alterations were detected by WES of the tumor DNA of the patient at initial presentation and surgical resection of EGFR-mutant lung cancer (R1), at the time of development of metastatic disease (R2), on progression to first-line treatment with erlotinib (Erl) (R3), and at autopsy after treatment with the second-line EGFR TKI rociletinib, which was followed by progressive disease and death (R4-R7) (description of analysis in Online Methods). R-and L-denote right and left, respectively. (b) Phylogenetic tree illustrating the evolutionary history of the patient's disease at the level of subclonal clusters of mutations. These subclonal clusters were inferred, using PyClone, from the samples taken from the primary and different metastases at multiple time points. The mutations were clustered on the basis of their prevalence (subclonal copy number-corrected cancer cell fraction) in the sequenced cancer cell populations across all samples, and this clustering was then used to infer the founding clone (at the bottom of the tree) and subclonal clusters. A r t i c l e s on second-line therapy (q values determined by two-tailed Fisher's exact test with Benjamini-Hochberg correction for multiple hypotheses; Fig. 3d and Supplementary Data Set 3).
We investigated detectable differences in cfDNA between EGFR TKI responders and nonresponders in 73 samples from 64 patients with known response to subsequent EGFR TKI treatment (Supplementary Table 6 ). The mean number of functional alterations detected in cfDNA was lower in patients who responded (n = 37, 2. Fig. 3a,b) . Patients whose cfDNA contained CDK4 or CDK6 gene alterations (n = 7) also Cell number (×10 A r t i c l e s exhibited shorter progression-free survival (PFS) (hazard ratio (HR) 13.8, 95% CI [5.1-36.8], P = 1.4 × 10 −11 , Cox proportional-hazard regression test; Supplementary Fig. 3c,d Fig. 3f-h) were biomarkers of shorter PFS during subsequent EGFR TKI treatment. Patients with CDK4 or CDK6 alterations (n = 7) exhibited lower overall survival than did patients without those alterations (n = 66) (HR 5.4, 95% CI [1.7-18.0], P = 0.002, Cox proportionalhazard regression test; Supplementary Fig. 4 ). These data suggested selection for increased genetic diversity during iterative tumor progression on therapy and identified biomarkers of poor response to EGFR TKI treatment (i.e., alterations in cell-cycle and MAPKpathway genes). We observed further evidence for this selection in a cohort of several individual clinical cases of EGFR-mutant NSCLC in which intrapatient longitudinal cfDNA profiling was performed (Supplementary Fig. 5 ).
cfDNA analysis linked to differential osimertinib response Although mechanisms of acquired resistance to the third-generation EGFR TKI osimertinib have been well described [14] [15] [16] [17] , mechanisms of primary resistance have not been well characterized. We identified 41 patients who underwent cfDNA analysis before treatment with osimertinib for whom clinical response, PFS, and overall survival after subsequent osimertinib treatment were known (Supplementary Table  6 and Supplementary Data Set 4). Alterations in MET (3/21), NF1 (5/21), CDK4 (3/21), CCNE1 (3/21), CDK6 (2/21), PIK3CA (6/21), and APC (5/21) were found only in patients with primary resistance to osimertinib treatment (Fig. 4a,b Fig. 4c,d) , although no statistically significant differences in overall survival were observed (Supplementary Fig. 4c) . Fig. 4d ). These data highlight potential roles for MAPK-, PI3K-, and WNTpathway alterations in driving primary resistance to osimertinib and uncover cell-cycle-gene aberrations (specifically in CDK4 or CDK6) as clinical biomarkers of osimertinib nonresponse (i.e., primary resistance) in advanced-stage EGFR p.Thr790Met-positive NSCLC. Thus, co-occurring genetic alterations may function as codrivers of tumor progression and drug resistance and may create genetic diversity that is advantageous for cancer evolution.
Longitudinal spatiotemporal genomic profiling
We next leveraged the uncommon opportunity to analyze a NSCLC clinical case through both tumor-based whole-exome sequencing (WES) and cfDNA profiling over 6 years of disease progression, from the initial diagnosis of surgically resectable disease through metastatic progression, first in mediastinal lymph nodes, then in the lungs, bone, and brain, during which the patient was treated with erlotinib followed by the third-generation EGFR TKI rociletinib 18 ( Supplementary Fig. 6 ). Seven tumor specimens (four lung, two A r t i c l e s bone, and one lymph node), including four obtained at autopsy after lethal tumor progression under rociletinib treatment, and six plasma specimens were analyzed longitudinally. The WES analysis showed that >75% of the coding mutational burden was truncal (ubiquitous and clonal) at diagnosis, but this proportion decreased to 50-58% at the time of full cancer evolution (patient death) via the emergence of subclonal mutations through tumor progression and first-and second-line EGFR TKI treatment and resistance (Fig. 5a) . The genetic co-alterations present in this patient by longitudinal tumor-based exome sequencing were consistent with the results of our cfDNA analysis of the broader cohort of advanced-stage EGFR-mutant NSCLC (Figs. 1-4) , with evidence of cell-cycle, WNT-pathway, and PI3K-pathway alterations. Multiple functionally relevant somatic co-alterations were present in earlystage disease (R1), including the clonal and truncal EGFR variant c.2233_2252delinsAATT:chr7:g.55242463_55242482delinsAATT (hg19) (p.Glu746_Thr751delinsLeu; NM_005228), CTNNB1 variant c.110C>T, chr3:g.41266113C>T (hg19) (p.Ser37Phe; NM_001904) 19 , SMAD4 variant c.437T>G, chr18:g.48575677T>G (hg19) (p.Leu146*; NM_005359) and RBM10 variant c.269C>A, chrX:g.47032594C>A (hg19) (p.Ser10*; NM_005676) as well as CDKN2A copy number loss (Fig. 5a,b, Supplementary Fig. 7 and Supplementary Data Sets 5 and 6). Acquisition of PRKCA variant c.1403_1404AC>TA, chr17:g.64738757-64738758AC>TA (hg19) (p.Asn468Ile; NM_ 002737) 20 and PIK3CA variant c.317G>T, chr3:g.178916930G>T (hg19) (p.Gly106Val; NM_006218) 21 , and CNG in the genomic region containing EGFR, CDK6, MET, and BRAF all occurred after mediastinal lymph node metastasis (R2) (Fig. 5a-c, Supplementary  Fig. 7 and Supplementary Data Sets 5 and 6). Progression under initial EGFR TKI (erlotinib) treatment occurred with acquisition of the EGFR variant c.2369C>T, chr7:g.55249071C>T (hg19) (p.Thr790Met; NM_005228), found in ~60% of patients with EGFRmutant NSCLC progressing under first-generation EGFR TKI treatment 11 , and the persistence of additional co-alterations including CTNNB1 variant p.Ser37Phe and PIK3CA variant p.Gly106Val. Our data suggested that the PIK3CA variant p.Gly106Val arose before both EGFR TKI treatment and EGFR variant p.Thr790Met ( Fig. 5a and Supplementary Fig. 8 ). The data suggested that the EGFR variant p.Thr790Met arose twice in this case in a previously unreported instance of independent dual clones, because it was found in metastatic sites containing PIK3CA variant p.Gly106Val (R3, left-lung progression under erlotinib; R4, left-lung progression under rociletinib, and R6, right-lung progression under rociletinib) and those that did not (R5, right-rib metastasis; R7, spine metastasis), although despite relatively deep sequencing coverage (250-to 600-fold across the tumor samples), we cannot completely rule out that a rare subclonal common progenitor cell bearing EGFR p.Thr790Met might have existed in the primary tumor (Fig. 5a-c and  Supplementary Fig. 8 ). Additional subclonal genetic co-alterations, including PIK3CA c.3140A>G, chr3:g.178952085A>G (hg19) (p.His1047Arg; NM_006218) (R5, right rib), RB1 c.2570G>A, chr13: g.49050886G>A (hg19) (p.Arg857His; NM_000321) (R4, left lung), CHD4 c.3452A>C, chr12:g.6697477T>G (hg19) (p.His1151Pro; NM_ 001273) (R6, right lung), and TLR4 c.866G>A, chr9 g.120475272G>A (hg19) (p.Arg289Gln; NM_138554) (R5, right rib) arose with tumor progression under rociletinib treatment (Fig. 5a-c) . The activating PIK3CA variant p.Gly106Val 21 was not found in all of the postrociletinib metastatic sites (present in R4 and R6; absent in R5 and R7), thus demonstrating lesion-specific heterogeneity (Fig. 5a,b) . The subclonal PIK3CA oncogenic variant p.His1047Arg 22 was found in R5 (right rib, post-rociletinib), thus suggesting another instance of parallel evolution in this cancer: two different PIK3CA oncogenes (Fig. 5a-c and Supplementary Fig. 8 ). Although the RB1 variant p.Arg857His was detected in R4 (left lung, progression under rociletinib), and RB1 inactivation is associated with transition from lung adenocarcinoma to small-cell carcinoma after EGFR TKI resistance is acquired 23, 24 , there was no evidence of transition to small-cell histology in this case, perhaps because of the absence of a somatic TP53 alteration (Supplementary Fig. 6 ).
Although plasma samples for cfDNA analysis were unavailable for the initial clinical events (before erlotinib treatment), coupling serially acquired cfDNA data (Online Methods) with tumor-biopsybased WES showed examples of ubiquitous (EGFR p.exon19del and CTNNB1 p.Ser37Phe) and lesion-restricted (PIK3CA p.Gly106Val , RB1 p.Arg857His, and TLR4 p.Arg289Gln) mutations in the plasma (Fig. 5d) . Thus, cfDNA analysis integrates multiple metastatic tumor lesions.
Functional importance of co-occurring genomic alterations
Similarly to the findings for our larger cohort of patients with EGFRmutant NSCLC (Fig. 1-4) , our results highlight the co-occurrence of genetic alterations within the WNT (CTNNB1 variant p.Ser37Phe), PI3K (PIK3CA variant p.Gly106Val), and cell-cycle (CDK6 CNG, and CDKN2A loss) pathways. We hypothesized that such co-occurring alterations might function nonredundantly in driving tumor metastasis or might limit targeted therapy response, a hypothesis for which we provide experimental evidence (Supplementary Note, Supplementary  Fig. 9 and Fig. 6 ). . We propose that advanced-stage EGFR-mutant NSCLCs contain co-occurring genetic alterations that function collaboratively as codrivers of tumor progression and drug resistance. We now need to identify and cotarget these co-occurring functional genetic alterations beyond mutant EGFR itself in patients, early and dynamically during treatment, in order to improve patient survival. The finding of extensive co-occurring alterations within advanced-stage EGFR-mutant NSCLC at scale now paves the way for studying the biological and clinical effects of genetic interactions that are created by the co-alterations present in these EGFR-mutant NSCLCs.
A r t i c l e s
Clonal analysis of genetic alterations detected in cfDNA Our data (Fig. 5) suggested that subclonal co-occurring oncogenic driver events can influence tumor progression and response to EGFR TKI treatment. To assess whether subclonal events are common in advanced-stage EGFR-mutant lung cancers more broadly, we assessed whether co-occurring genetic alterations detected in the cfDNA of 1,122 patients with advanced-stage EGFR-mutant NSCLC were clonal or subclonal (Supplementary Note and Supplementary Fig. 10 25 . The subclonal frequency of other common variants is also described (Supplementary Note).
DISCUSSION
This study sheds new light on the genetic basis of oncogenesis and cancer progression by showing that multiple co-occurring oncogenic events are present in most advanced-stage EGFR-mutant lung cancers. These new data call into question the current view of the genetic basis of EGFR-mutant lung cancer as a single-oncogene disease wherein oncogenic-mutant EGFR is mutually exclusive from any other oncogene (Fig. 8) . Our findings highlight the importance of deploying more informed and genomically empowered molecular diagnosis, monitoring, and dynamically applied rational polytherapy strategies to address the clonal and subclonal co-alterations that drive disease progression and drug resistance, in order to better control this deadly cancer. Our results are reminiscent of recent findings in myeloproliferative neoplasms 26 and prompt reexamination of the presence and clinical effects of co-occurring genetic alterations in other cancer types by using large data sets, such as the one used herein, to enable a powered analysis. We identified new pathways that promote EGFR-mutant lung cancer progression and limit EGFR TKI response. Examples include WNT/β-catenin and cell-cycle gene alterations and cell-cycle-gene mutations (Figs. 4-6 and Supplementary Note). Overall, the widespread presence, evolution, and clinical effects of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers uncovered here reshape the current view of oncogene-positive lung cancer and offer future directions for both basic and clinical research that hold promise for improving current treatments for this aggressive cancer. 
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ONLINE METHODS
Patients. IRB approval for the study (no. was granted by the UCSF IRB on May 13, 2016 . Per the UCSF IRB, the study did not involve human subjects, as defined by the federal regulations summarized in 45 CFR 46.102(f). Hence, further IRB oversight was not required, and the requirement for informed consent was waived. For EGFR-mutation-positive and EGFR-mutation-negative cohorts, selection criteria for inclusion were met if patients had a known diagnosis of stage III or stage IV NSCLC. For EGFR-mutation-positive NSCLC, the analysis included 1,122 consecutive samples collected in March 2015 to April 2016 from 1,006 patients in whom a nonsynonymous mutation in EGFR of known or predicted functional significance (described below) was identified in the Guardant 360 clinical assay. EGFR CNG by itself was included in the EGFR-mutation-negative cohort. The EGFR-mutant-negative cohort consisted of all other patients with advanced-stage NSCLC from the time period of January 2016 to April 2016 (1,008 samples from 999 patients). Chart review of EGFR-mutant Guardant cases from patients at UCSF, UCSD, UC Davis, and the University of Colorado was carried out by the study investigators to identify patient demographic information and to determine when the Guardant 360 assay was sent in relation to the patients' treatment course. Objective response, PFS, and overall survival to EGFR TKI therapy were determined by retrospective chart review for clinical assessment and direct radiographic review by study investigators when possible. Composite clinical evaluation that integrated clinical and radiographic information was used to discriminate responders from nonresponders. (Responders were defined as showing radiographic and/or clinical improvement, on the basis of investigator assessment; nonresponders were defined as showing radiographic stable disease or progressive disease (by RECIST 1.1 criteria, or clinical decline, or death before imaging). The time-to-event outcomes, including PFS and overall survival were estimated with the Kaplan-Meier method.
Cell-free DNA analysis. Samples were shipped to a Clinical Laboratory Improvement Act (CLIA)-certified, College of American Pathologistsaccredited laboratory (Guardant Health). cfDNA was extracted from whole blood collected in 10-mL Streck tubes. After double centrifugation, 5-30 ng of cfDNA was isolated for digital sequencing as previously described 9, 27 . For EGFR-mutant-positive NSCLCs, samples were run on a 68-gene panel or 70-gene panel, but only the 68 genes in common were included in this analysis (Supplementary Table 2 ). Sequencing data were analyzed with the Guardant Health clinical analysis bioinformatics pipeline to identify single-nucleotide variants (SNVs) in 68 genes (150-kb panel footprint), CNGs in 16 genes, indels in EGFR, and fusions in ALK, RET, ROS1, NTRK1, FGFR2, and FGFR3 (refs. 9, 27) . All cell-free leukocyte-and tumor-derived DNA fragments were simultaneously sequenced. The variant allele fraction (VAF) was calculated as the proportion of cfDNA bearing the variant in a background of wild-type cfDNA. Reporting thresholds for SNVs, indels, and fusions were one or two molecules and 0.01-0.04% allelic fraction with 0.2-0.3% 95% limits of detection and >99.9999% per-position analytical specificity 9, 27 . To identify CNGs in a large training set, probe-level unique-molecule coverage was normalized for signal saturation, individual-probe efficiency, GC content, and overall uniquemolecule throughput, and was robustly summarized to generate a quantitative gene-level unique-molecule representation. Relative quantification was determined by comparison of this representation to the inferred diploid baseline on a per-gene level. Reporting thresholds were based on training-set-established decision thresholds for both absolute copy number deviation from the persample diploid baseline and deviation from the baseline variation of probelevel-normalized signal in the context of background variation within each sample's own diploid baseline. The reporting threshold for CNGs was 2.12 copies with a 2.24-2.76 gene-specific 95% limits of detection and 100% analytical specificity. For clonality analysis, first, the mutational allele frequency (MAF) was normalized by the copy numbers of the same genes with CNGs, and the largest MAF within each was selected as the normalized maximum MAF; second, the ratio of the MAF of each mutational allele over the maximum percentage detection within a case was computed, and the probability distribution was plotted by using kernel density estimation. To determine the cutoff of the percentage of normalized MAF as clonal or subclonal of each mutation, we implemented the aforementioned algorithms to the case with both tumor tissue exome sequencing and cfDNA sequencing encoding EGFR exon19del, EGFR p.Thr790Met, PIK3CA p.Gly106Val, CTNNB1 p.Ser37Phe, RB1 p.Arg857His, and TLR4 p.Arg289Gln reported in this study ( Fig. 5 and Supplementary Fig. 10 ). The value of 0.2 was defined as a robust cutoff for subclonal or clonal mutations, thus resulting in 100% sensitivity and 100% specificity, because all somatic variants identified through this method as subclonal or clonal in cfDNA were also correctly identified as subclonal or clonal in patient tumor samples (Supplementary Fig. 10 ). For the longitudinal case (Fig. 5d) , cfDNA was isolated from 1 ml of frozen plasma and analyzed as previously described 5, 28 . Clinical data were collected by review of medical records under an IRB-approved protocol (UCSF). Nonsynonymous mutations from EGFR-mutant-positive and EGFR-mutant-negative data sets were further processed with the R statistical computing program (version 3.3). Unknown significant variants were filtered out by using COSMIC (V79), GENIE, and prediction algorithms (URLs).
Whole-exome sequencing and analysis. Informed consent was obtained from the patient and patient's family for study of biological materials and clinical records obtained from the patient. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) primary and frozen tumor tissue samples and matched nontumor tissue with a Qiagen Allprep DNA/RNA Mini Kit. The library preparation protocol was based on the Agilent SureSelect Library Prep and Capture System (Agilent Technologies). Quantification and quality were assessed with a Qubit Fluorometer (Thermo Fisher). DNA concentration was determined to be greater than 2.5 ng/ìL, and the overall quantity was >500 ng. Analysis with a NanoDrop spectrophotometer indicated that the 260/280 ratio was >1.7. DNA was resuspended in a low-TE buffer and sheared (duty cycle, 5%; intensity, 175; cycles/burst, 200; time, 300 s) with a Covaris S2 Ultrasonicator Barcoded exome libraries were prepared with an Agilent Sure Select V5 library kit, per the manufacturer's specifications. The libraries were run on the HiSeq2500 platform.
Alignment. Raw paired-end reads (100 bp) in FastQ format generated by the Illumina pipeline were aligned to the full hg19 genomic assembly obtained from USCS, gencode 14, with bwa version 0.7.12. Picard tools version 1.117 was used to sort, remove duplicate reads, and generate QC statistics. Tumor DNA was sequenced to a median depth of 303× (range 114.39-383.41), and the matched germline DNA was sequenced to an average depth of 231.65.
Exome analysis. SNV, indel, and dinucleotide-substitution calling; identification and classification of driver mutations; somatic copy number-aberration calling; subclonal deconstruction; and phylogenetic-tree construction were performed as previously described 29 .
Classification of somatic copy number alterations (SCNAs). SCNA events were defined as segments called by ASCAT that were ≥400 kb in size and met set thresholds. Segments with a combined raw nMinor and nMajor >1.5 times the ASCAT-derived ploidy for their specific tumor region were considered SCNA gains. SCNA losses had an integer nMinor value of 0 and a combined raw nMinor and nMajor of less than 1.25 times ploidy for their specific tumor region.
Incorporation of the EGFR p.Thr790Met mutation into phylogenetic reconstruction. To create an accurate subclonal phylogeny, it is necessary to remove mutation clusters that violate two evolutionary principles. First is the 'pigeonhole principle' , wherein two mutation clusters cannot be considered to be on separate branches of an evolutionary tree and thus to be independent if the cancer cell fraction values of the two clusters together exceed 100% within region of a tumor. Second is the 'crossing rule' , wherein a descendent clone is required to have a smaller cancer cell fraction than its ancestor within each and every tumor region. With these principles, it can be determined whether particular mutation clusters conflict with each other and cannot be fitted to the same evolutionary tree.
The subclonal phylogeny illustrating the entire course of the patient's disease was derived by following these two principles and the methods of multisample subclonal deconstruction and tree construction in ref. 29 . However, the SNV encoding EGFR p.Thr790Met did not cluster with any other SNVs through these methods, owing to its unique cancer-cell-fraction profile across (mean 1 -mean 2 )/s.d. pooled , where s.d. pooled = (s.d. 1 + s.d. 2 )/2; proportions tests were used for two-population proportion comparison with 95% confidence intervals, and no correction was used. In some conditions, the 95% confidence interval for the single-population proportion was used. OR values were calculated as a measure of the effect size between two populations with proportion comparison. For assessments of PFS (Fig. 4 and Supplementary  Fig. 3 ) and overall survival ( Supplementary Fig. 4) , the 95% CI for the median duration of PFS and overall survival were computed with the robust nonparametric Brookmeyer and Crowley method. HRs with 95% CI and P values were calculated with the 'Cox proportional-hazards regression model with survival' package in R. For qPCR, cell growth, invasion, and migration analysis (Fig. 6) one-way ANOVA with Bonferroni correction were used to determine P values (GraphPad Prism).
Code availability. Most bioinformatics tools used in the analysis of this data set are publicly available; any that are not are available on request.
Data availability. The data supporting the findings of the study are available within the paper and its supplementary information files and have been deposited publically in the European Genome-phenome Archive (EGA) under accession number EGAS00001002604. A Life Sciences Reporting Summary for this paper is available.
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Policy information about availability of computer code
Describe the software used to analyze the data in this study.
Open source R program was used for data visualization and statistic analysis as described in Methods. Whole exome sequencing data was performed according to the Tracer-X pipeline published in Jamal-Hanjani, For all studies, we encourage code deposition in a community repository (e.g. GitHub). Authors must make computer code available to editors and reviewers upon request. The Nature Methods guidance for providing algorithms and software for publication may be useful for any submission.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a for-profit company.
There are no restrictions on availability of unique materials. c. Report whether the cell lines were tested for mycoplasma contamination.
The HCC827 (EGFR exon 19 deletion) and HEK293-FT cell lines confirmed to be negative for mycoplasma.
d. If any of the cell lines used in the paper are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
